Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retinal branch vein rt-PA for central retinal vein occlusion
NL-OMON24763Suspended
- Sponsor
- Het Oogziekenhuis Rotterdam
- Start
- Jul 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of tissue-plasminogen activator in central retinal vein occlusion (CRVO) (2 arms), sponsored by Het Oogziekenhuis Rotterdam. Primary endpoint: Best-corrected visual acuity on ETDRS chart. Started Jul 2006; status: suspended.
02
Drugs
tissue-plasminogen activator
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NL-OMON24763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24763.